7 results match your criteria: "General Hospital of Larissa "Koutlibanio"[Affiliation]"
Infectious complications of transrectal prostate biopsy in patients receiving targeted antibiotic prophylaxis after urethral and rectal swab versus standard prophylaxis: A prospective comparative study.
Prostate Int
March 2024
Medical School, University of Cyprus, Nicosia, Cyprus.
Article Synopsis
- A study was conducted to compare the effectiveness of targeted antibiotic prophylaxis (TAP) versus empiric antibiotic prophylaxis (EAP) in preventing infections after prostate biopsy.
- The study involved 141 patients, where the EAP group had a higher infection rate (9.85%) compared to the TAP group (1.4%), showing that TAP significantly reduces infection risks.
- Findings indicated that rectal and urethral swab cultures can help identify antibiotic-resistant bacteria, leading to improved treatment outcomes.
Emerging Role of YAP and the Hippo Pathway in Prostate Cancer.
Biomedicines
November 2022
Department of Medical Oncology, University General Hospital of Larissa, 41221 Larissa, Greece.
The Hippo pathway regulates and contributes to several hallmarks of prostate cancer (PCa). Although the elucidation of YAP function in PCa is in its infancy, emerging studies have shed light on the role of aberrant Hippo pathway signaling in PCa development and progression. YAP overexpression and nuclear localization has been linked to poor prognosis and resistance to treatment, highlighting a therapeutic potential that may suggest innovative strategies to treat cancer.
View Article and Find Full Text PDFMonoclonal Antibody Therapy for the Treatment of Interstitial Cystitis.
Biologics
May 2022
First Urology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Article Synopsis
- New theories suggest that painful bladder syndrome/interstitial cystitis (PBS/IC) might be autoimmune, prompting studies on immunotherapy options for treatment.
- A review evaluated the effectiveness of monoclonal antibodies, focusing on adalimumab (no significant results) and certolizumab pegol (showed positive results) for PBS/IC patients.
- Other treatments like anti-nerve growth factor agents showed mixed results, indicating more research is needed before monoclonal antibody therapy can be confirmed as a viable treatment option for PBS/IC.
Efficacy of fesoterodine fumarate (8 mg) in neurogenic detrusor overactivity due to spinal cord lesion or multiple sclerosis: A prospective study.
Neurourol Urodyn
November 2021
Department of Urology, School of Medicine, University of Patra, Patras, Greece.
Aims: Antimuscarinic drugs are the first-line choice in the treatment of patients with neurogenic Detrusor Overactivity (nDO). Fesoterodine fumarate is the newest antimuscarinic drug. Limited data are published about the use of fesoterodine fumarate in patients suffering from neurogenic lower urinary tract dysfunction.
View Article and Find Full Text PDFOptimal bladder diary duration for patients with suprapontine neurogenic lower urinary tract dysfunction.
Int Braz J Urol
July 2017
Department of Urology, General Hospital of Larissa "Koutlibanio", Larissa, Greece.
Purpose: To identify the minimum bladder diary's length required to furnish reliable documentation of LUTS in a specific cohort of patients suffering from neurogenic urinary dysfunction secondary to suprapontine pathology.
Materials And Methods: From January 2008 to January 2014, patients suffering from suprapontine pathology and LUTS were requested to prospectively complete a bladder diary form for 7 consecutive days. Micturitions per day, excreta per micturition, urgency and incontinence episodes and voided volume per day were evaluated from the completed diaries.
Renal artery embolism: a rare cause of acute abdominal or flank pain and the significance of early diagnosis.
Minerva Urol Nefrol
December 2014
Department of Urology, "Koutlibanio" General Hospital of Larisa, Larissa, Greece -
A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.
Int Braz J Urol
September 2014
Department of Urology, ″Koutlibanio″ General Hospital of Larisa, Larissa, Greece.
Objectives: To review the literature and present new data of continuous androgen deprivation therapy (ADT) vs intermittent androgen deprivation (IAD) as therapies for prostate cancer in terms of survival and quality of life and clarify practical issues in the use of IAD.
Materials And Methods: We conducted a systematic search on Medline and Embase databases using ″prostatic neoplasm″ and ″intermittent androgen deprivation″ as search terms. We reviewed meta-analyses, randomised controlled trials, reviews, clinical trials and practise guidelines written in English from 2000 and onwards until 01/04/2013.